** Shares of drugmaker BioCryst Pharmaceuticals BCRX.O rise 17.5% to $10.49 premarket
** BCRX raises its 2025 revenue forecast for its skin disease drug, Orladeyo, to between $580 million and $600 million, compared with previous projection of $535 million to $550 million
** Analysts on average estimate Orladeyo's 2025 revenue to be $514.29 million
** Co posts Q1 total revenue of $145.5 million, compared with $92.8 million a year ago
** BCRX reports Q1 revenue for Orladeyo of $134.2 million, compared with $88.9 million a year ago
** "Orladeyo's revenue growth was driven by moving patients from free drug to paid at a much faster rate than we expected, resulting in a substantial increase to our annual guidance as we also move closer to peak sales of $1 billion," says CEO Jon Stonehouse
** As of last close, BCRX rose 18.8% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。